Items Tagged ‘Nerlynx HER1’

November 1, 2017

Nerlynx Modestly Improves Survival of HER 2-Positive Early Stage Breast Cancer


Positive results from the clinical trial evaluating neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer following trastuzumab-based therapy (ExteNET trial) were presented at the European Society of Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. About HER2-Positive Breast Cancer Approximately 20% to 25% of breast cancers over-express the HER2 protein. HER2-positive […]

View full entry

Tags: Breast Cancer, HER-2, HER4 Positive Early Stage Breast Cancer, herceptin, Nerlynx HER1, News, Precision Cancer Medicine, trastuzumab